Physician profile
Lorena Dollani
NPI 1487040275
$1,928.87
in general payments reported to CMS, 2019-2025
14 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $110 · 2021: $69.00 · 2022: $421 · 2023: $72.48 · 2024: $706 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $458.78 | 2019-2024 | |
| Abbvie INC. | $326.36 | 2022-2025 | |
| Galderma Laboratories, L.P. | $253.79 | 2020-2025 | Nemluvio |
| Genzyme Corporation | $218.49 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.87 | 2020-2025 | Siliq, Jublia, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $108.50 | 2022 | |
| Janssen Biotech, INC. | $93.29 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $86.79 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $56.78 | 2025 | Anzupgo |
| Lilly USA, LLC | $55.25 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $35.84 | 2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $29.88 | 2024 | |
| Ucb, INC. | $28.18 | 2025 | Bimzelx |
| Botanix Sb INC | $17.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Dollani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.